Rett Syndrome
Introduction
Rett syndrome was first described in 1966 by the Austrian pediatric neurologist Andreas Rett. He observed a group of girls with developmental regression, loss of purposeful hand use, and characteristic stereotypic hand movements. Despite this early description, the diagnosis remained largely unrecognized internationally until 1983, when Bengt Hagberg and colleagues published a larger case series that clearly delineated Rett syndrome as a distinct clinical entity. A major milestone in understanding the disorder occurred in 1999, when mutations in the MECP2 gene were identified as the primary genetic cause, providing a molecular basis for the condition.
Epidemiology
RS has an estimated prevalence of approximately 1 in 10,000 to 15,000 live female births and occurs worldwide without clear geographic or ethnic variation. This syndrome predominantly affects females based on X-linked dominant inheritance. It is rarely seen in males, and in this case, it is usually associated with severe neonatal encephalopathy or specific chromosomal aberration such as Klinefelter syndrome. Most cases arise sporadically due to de novo mutations rather than inherited genetic mutations.
Genetics
Rett syndrome is caused by mutations in the MECP2 (Methyl-CpG Binding protein 2) gene located on the X chromosome (Xq28). This gene encodes methyl-CpG-binding protein 2, which plays a crucial role in regulating gene expression in the central nervous system by binding to methylated DNA. The condition follows an X-linked dominant pattern of inheritance, although most cases are due to new mutations rather than familial transmission. Because males have only one X chromosome, pathogenic variants are often lethal or lead to severe neonatal presentations, whereas females survive due to random X-chromosome inactivation, resulting in mosaic expression of the mutation.
Pathophysiology
The pathophysiology of this syndrome reflects a neurodevelopmental disorder based on a neurodegenerative process. Dysfunction of the MECP2 protein causes widespread abnormalities in transcriptional regulation, which, in turn, disrupt neuronal maturation, plasticity, and synaptic development. Impaired neurons exhibit reduced dendritic arborization and spine density, which in turn impairs connectivity within neural networks. There is also an imbalance between excitatory and inhibitory neurotransmission, along with alterations in several neurotransmitter systems, including glutamatergic, GABAergic, and monoaminergic pathways. Although brain growth is reduced, particularly after birth, there is no significant neuronal loss, distinguishing Rett syndrome from classical neurodegenerative disorders.
Clinical Manifestations
Rett syndrome almost always follows a characteristic clinical course with distinct stages. In the early-onset stage, usually between 6 and 18 months of age, development may appear normal at first, but subtle delays become apparent, including reduced eye contact, hypotonia, and slowed head growth. This is followed by a phase of rapid regression between 1 and 4 years of age, during which previously acquired skills, particularly purposeful hand use and spoken language, are lost. During this stage, characteristic hand stereotypies emerge, such as hand wringing, clapping, or washing movements, and social withdrawal may resemble features of autism. In the subsequent plateau phase, typically occurring in preschool and school-age children, developmental regression stabilizes, and some improvement in social interaction may occur. Although severe intellectual disability persists, and epileptic seizures frequently develop.
In the later stages, often after age 10, there is progressive motor deterioration, with increasing rigidity, dystonia, scoliosis, and loss of ambulation in many individuals. The main clinical features include severe intellectual disability, loss of purposeful hand function, stereotypic hand movements, gait abnormalities or inability to walk, acquired microcephaly, and profound impairment in communication. In addition, a range of associated features is common, including epilepsy, breathing abnormalities such as hyperventilation and apnea during wakefulness, autonomic dysfunction, sleep disturbances, scoliosis, growth failure, and cardiac abnormalities such as prolonged QT interval.
Dysautonomia is a common feature of Rett syndrome and reflects impaired regulation of the autonomic nervous system. It can manifest as irregular breathing patterns (such as hyperventilation or breath-holding), heart rate variability, peripheral vasomotor instability, and gastrointestinal dysmotility. These disturbances may fluctuate over time and can contribute significantly to morbidity, including an increased risk of cardiac arrhythmias and sudden death.
Diagnosis
The diagnosis of Rett syndrome is mainly clinical and is confirmed according to established diagnostic criteria. These criteria include an initial developmental regression followed by a stabilization period, along with typical clinical features such as loss of purposeful hand skills and stereotypic hand movements. Genetic testing for mutations in the MECP2 gene confirms the diagnosis in the majority of individuals with classic Rett syndrome. Differential diagnoses include autism spectrum disorder, cerebral palsy, CDKL5 deficiency disorder, FOXG1 syndrome, and other causes of developmental regression. Additional investigations can provide supportive evidence for the diagnosis. These include electroencephalography, which may reveal nonspecific abnormalities or epileptiform activity; brain MRI, which can show reduced brain volume or other nonspecific changes; and electrocardiography to evaluate for QT interval prolongation.
Treatment
There is currently no cure for RS, and management is centered on symptomatic and supportive care delivered through a multidisciplinary approach. Pharmacological treatment is mainly aimed at associated conditions, particularly epilepsy, as well as sleep disturbances, behavioral symptoms, and motor features such as spasticity or dystonia. Non-pharmacological interventions are a key component of management and include physiotherapy to preserve mobility and prevent contractures, occupational therapy to enhance functional skills, and speech and communication support incorporating augmentative and alternative communication strategies. Nutritional support is frequently necessary due to feeding difficulties and poor growth. Regular monitoring and follow-up are essential to detect and manage complications such as scoliosis, cardiac arrhythmias, and nutritional deficiencies.
Novel therapeutic strategies, including gene therapy and disease-modifying treatments, are currently under investigation. Novel therapeutic agents, such as trofinetide and insulin-like growth factor-1 analogs, are being explored and may represent future treatment options.
Prognosis
Rett syndrome is a lifelong condition associated with severe disability, although many affected individuals survive into adulthood, often into their fourth or fifth decade or beyond. The prognosis varies according to the severity of subsequent complications, including epileptic seizures, the extent of motor impairment, and the presence of comorbidities such as scoliosis and cardiac abnormalities. Morbidity is largely related to neurological impairment, immobility, and systemic complications, while mortality is most often associated with respiratory dysfunction, cardiac arrhythmias, and complications secondary to reduced mobility. Despite significant limitations, many individuals experience periods of relative stability, and supportive care can substantially improve quality of life.
